Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced upcoming data presentations on etripamil at ISPOR 2024 being held in Atlanta, GA on May 5-8, 2024, the 2024 Stanford BioDesign Arrhythmia Technologies Retreat in Boston, MA, on May 15, 2024, and the Annual meeting of the Heart Rhythm Society, Heart Rhythm 2024, in Boston, MA on May 16-19, 2024. The poster presentations will be available following each embargo at:
蒙特利爾和北卡羅來納州夏洛特，2024 年 5 月 2 日（GLOBE NEWSWIRE）——里程碑 專注於創新心血管藥物開發和商業化的生物製藥公司製藥公司（納斯達克股票代碼：MIST）今天宣佈，即將在2024年5月5日至8日在喬治亞州亞特蘭大舉行的ISPOR 2024、2024年5月15日在馬薩諸塞州波士頓舉行的斯坦福生物設計心律失常技術務虛會以及在馬薩諸塞州波士頓舉行的心律學會年會《2024年心律失常》年會上發佈依曲米的數據報告 2024 年 5 月 16 日至 19 日。每次禁運後，海報展示將在以下網址公佈：
| ISPOR | |
| Poster Presentation Title: | Analysis of Healthcare Resource Utilization in the NODE-303 Clinical Trial to Terminate Supraventricular Tachycardia (SVT) Episodes |
| Presenter: | John Jackimiec, RPh., MBA |
| Date and time: | May 6, 3:30 pm EDT |
| 2024 Stanford BioDesign Arrhythmia Technologies Retreat | |
| Poster Presentation Title: | Etripamil Nasal Spray: Data for Acute Rate Control in Atrial Fibrillation with a Rapid Ventricular Rate (AFib-RVR) |
| Presenter: | David Bharucha, MD, PhD, FACC |
| Date and time: | May 15, 10 am EDT |
| Heart Rhythm 2024 | |
| Poster Presentation Title: | Self-Administered Etripamil Nasal Spray Rapidly Terminated Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT): Analysis of Open-Label Treatment in the RAPID Study |
| Presenter: | James Ip, MD, FACC, FHRS |
| Date and time: | May 18, 3:30 pm EDT |
| ISPOR | |
| 海報演示文稿標題： | 對終止室上性心動過速 (SVT) 發作的 NODE-303 臨床試驗中醫療資源利用情況的分析 |
| 演示者： | 約翰·傑基米克，博士，工商管理碩士 |
| 日期和時間： | 美國東部時間 5 月 6 日下午 3:30 |
| 2024 斯坦福生物設計心律失常技術務虛會 | |
| 海報演示文稿標題： | Etripamil 鼻腔噴霧劑：使用快速心室率（AFIB-RVR）控制心房顫動急性速率的數據 |
| 演示者： | David Bharucha，醫學博士，FACC |
| 日期和時間： | 美國東部時間 5 月 15 日上午 10 點 |
| 心律 2024 | |
| 海報演示文稿標題： | 自我給藥的Etripamil鼻腔噴霧劑可快速終止自發性陣發性室上性心動過速（PSVT）：對RAPID研究中開放標籤治療的分析 |
| 演示者： | James Ip，醫學博士，FACC，FHRS |
| 日期和時間： | 美國東部時間 5 月 18 日下午 3:30 |
About Milestone Pharmaceuticals
關於里程碑製藥
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company's focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Milestone Pharmicals Inc.（納斯達克股票代碼：MIST）是一家生物製藥公司，正在開發和商業化創新的心血管解決方案，以改善患有複雜和改變生活的心臟病患者的生活。該公司專注於了解未滿足的患者需求和改善患者體驗，這促使我們開發了新的治療方法，讓患者在自我管理護理方面發揮積極作用。Milestone的主要研究產品是etripamil，這是一種新型的鈣通道阻滯劑鼻腔噴霧劑，正在研究患者無需醫療監督即可自行服用，以治療與PSVT和AFIB-RVR相關的有症狀的發作性發作。
Contact:
聯繫人：
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
金·福克斯，傳播副總裁，kfox@milestonepharma.com
Investor Relations
投資者關係
Chris Calabrese, ccalabrese@lifesciadvisors.com
克里斯·卡拉布雷斯，ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com
凱文·加德納，kgardner@lifesciadvisors.com
譯文內容由第三人軟體翻譯。